CVX has added another 4.6% this week to $205.74, building on last week's recovery to $200 — and the most telling story now is what the two sides of the market are doing in response to a stock that has risen 35% year-to-date.
Morgan Stanley's energy analyst raised his price target to $218 from $210 this morning, maintaining an Overweight rating — the most recent and bullish move in a week where analyst direction has split. Barclays went the other way on Monday, trimming its target to $208 from $216, though it held its Equal-Weight stance. Below those, the broader analyst community has been nudging numbers higher: TD Cowen lifted to $205 and Bernstein to $209 earlier in the month, while BofA Securities carried the most optimistic view at $227. The consensus mean price target is $217.88, roughly 6% above current levels, and the analyst recommendation factor ranks in the 89th percentile of the universe — one of CVX's strongest scores. Bulls point to compounding production growth across Kazakhstan, Australia, and Argentina, a well-defended balance sheet, and a disciplined buyback record. Bears flag the reverse: heavy international exposure, political and execution risk, and a portfolio that looks increasingly concentrated on commitments extending past 2030.
The borrow market has essentially nothing to say about this rally. Short interest is just 0.97% of the free float — under the 1% threshold where it becomes interesting — and fell nearly 5% over the past five days as shorts continued the unwind that began in earnest last week. Borrow availability is effectively unlimited, with the lending pool vastly larger than demand. Cost to borrow ticked up about 14% week-on-week to 0.47%, but that is noise at this absolute level — still among the cheapest borrows in the energy sector. The ORTEX short score is running at 29.5, roughly flat for the past two weeks, which places CVX in the 76th percentile for low short pressure. This is not a story about squeeze dynamics or crowded positioning. It is the opposite: the lending market reflects a stock that bears have largely abandoned.
Options positioning is mildly more cautious than neutral, but only marginally so. The put/call ratio is 0.68, slightly above its 20-day average of 0.66, with a z-score under one — not a meaningful signal in either direction. The 52-week range for the PCR runs from 0.60 to 0.96, so the current reading is near the middle of the distribution. Traders are not rushing to hedge into next quarter.
The insider picture is harder to dismiss. CEO Mike Wirth sold just over 317,000 shares across two tranches on August 14 — combined proceeds of roughly $63.6 million. He also sold around $1 million of stock on August 5. Director John Hess sold more than 600,000 shares in multiple transactions on August 3, collecting approximately $116 million in aggregate. The 90-day insider net across the company runs to a net sell of roughly $298 million. These are plan-driven sales from executives managing concentrated positions, and trade significance scores are low. Even so, the timing — into a 35% year-to-date rally, with the stock now above most analyst targets published before July — is worth noting. The stock rallied through both sell windows rather than reacting to them, which is itself informative.
Peers broadly tracked CVX higher this week, though with dispersion. XOM gained 3.6% and EOG 3.7%, while COP added 3.0%. DVN outperformed the group at 5.4%. OXY was the laggard, up just 1.3%, suggesting the week's energy move was fairly sector-wide rather than CVX-specific. The next specific event for Chevron is Q3 earnings on October 30 — a print that, based on the July quarter, produced only a 0.45% next-day move before fading 3% over the following five sessions.
What to watch: whether the stock can hold above $205 — the level that has historically marked the upper end of analyst consensus — and how quickly the Morgan Stanley target upgrade at $218 brings other bulls to revise their models higher in the days ahead.
See the live data behind this article on ORTEX.
Open CVX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
